Published in Neuropharmacology on January 06, 2010
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain (2012) 1.04
Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis? J Cereb Blood Flow Metab (2014) 0.97
Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface. Front Cell Neurosci (2015) 0.96
Insulin and glucagon share the same mechanism of neuroprotection in diabetic rats: role of glutamate. Am J Physiol Regul Integr Comp Physiol (2011) 0.91
Method parameters' impact on mortality and variability in rat stroke experiments: a meta-analysis. BMC Neurosci (2013) 0.88
Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK. Am J Physiol Regul Integr Comp Physiol (2010) 0.85
Cytoprotective-selective activated protein C therapy for ischaemic stroke. Thromb Haemost (2014) 0.84
tPA regulates pulmonary vascular activity through NMDA receptors. Am J Physiol Lung Cell Mol Physiol (2011) 0.84
Vascular protection to increase the safety of tissue plasminogen activator for stroke. Curr Pharm Des (2012) 0.83
Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol (2012) 0.81
tPA-S(481)A prevents impairment of cerebrovascular autoregulation by endogenous tPA after traumatic brain injury by upregulating p38 MAPK and inhibiting ET-1. J Neurotrauma (2013) 0.78
Release of Matrix Metalloproteinases-2 and 9 by S-Nitrosylated Caveolin-1 Contributes to Degradation of Extracellular Matrix in tPA-Treated Hypoxic Endothelial Cells. PLoS One (2016) 0.77
Improved method for the preparation of a human cell-based, contact model of the blood-brain barrier. J Vis Exp (2013) 0.76
The Neuroprotective Effect of Rosemary (Rosmarinus officinalis L.) Hydro-alcoholic Extract on Cerebral Ischemic Tolerance in Experimental Stroke. Iran J Pharm Res (2016) 0.75
Integrated treatment modality of cathodal-transcranial direct current stimulation with peripheral sensory stimulation affords neuroprotection in a rat stroke model. Neurophotonics (2017) 0.75
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res (2007) 37.31
Glutamate neurotoxicity and diseases of the nervous system. Neuron (1988) 8.26
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke (2001) 4.64
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med (1998) 4.09
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 3.64
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest (2003) 3.41
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation (1999) 1.97
Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood (2000) 1.90
Protein Data Bank archives of three-dimensional macromolecular structures. Methods Enzymol (1997) 1.89
Serpin-resistant mutants of human tissue-type plasminogen activator. Nature (1989) 1.61
A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J Cell Mol Med (2008) 1.58
In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood (2003) 1.53
Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci (2006) 1.38
LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol (2006) 1.26
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res (2005) 1.23
Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J Neuroinflammation (2008) 1.22
Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A (1990) 1.13
Blood brain barrier permeability and acute inflammation in two models of traumatic brain injury in the immature rat: a preliminary report. Acta Neurochir Suppl (1998) 1.11
Structural quality assurance. Methods Biochem Anal (2003) 1.11
Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol (1995) 1.09
Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J (1997) 1.08
Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathol (1987) 1.07
Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo. FASEB J (2000) 1.04
Plasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusion. Brain Res (2009) 1.00
Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. Blood (1998) 0.97
Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. A role for defensin. J Biol Chem (1995) 0.95
Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke (2001) 0.95
Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma. Neuroreport (2001) 0.91
Restoration of serine protease-inhibitor interaction by protein engineering. J Biol Chem (1990) 0.88
Solution structure of the tissue-type plasminogen activator kringle 2 domain complexed to 6-aminohexanoic acid an antifibrinolytic drug. J Mol Biol (1991) 0.86
alpha-Defensin: link between inflammation and atherosclerosis. Atherosclerosis (2006) 0.85
Locoregional opening of the rodent blood-brain barrier for paclitaxel using Nd:YAG laser-induced thermo therapy: a new concept of adjuvant glioma therapy? Lasers Surg Med (2003) 0.81
Regulation of the single-chain urokinase-urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity. Blood (2004) 0.80
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol (2003) 2.03
Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost (2003) 1.91
How I treat heparin-induced thrombocytopenia. Blood (2012) 1.85
Structure of human urokinase plasminogen activator in complex with its receptor. Science (2006) 1.84
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
Nuclear translocation of urokinase-type plasminogen activator. Blood (2008) 1.66
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood (2004) 1.63
Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury. Am J Respir Crit Care Med (2008) 1.62
Dynamic antibody-binding properties in the pathogenesis of HIT. Blood (2012) 1.59
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood (2005) 1.59
In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood (2003) 1.53
Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood (2012) 1.50
Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood (2004) 1.50
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood (2012) 1.40
Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program (2004) 1.38
Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci (2006) 1.38
ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood (2003) 1.28
LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol (2006) 1.26
Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem (2002) 1.26
Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol (2006) 1.25
Determinants of PF4/heparin immunogenicity. Blood (2007) 1.25
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res (2005) 1.23
Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood (2002) 1.21
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. J Cereb Blood Flow Metab (2008) 1.18
Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood (2003) 1.18
Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J (2004) 1.17
Human alpha-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Blood (2002) 1.16
Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther (2004) 1.16
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood (2010) 1.14
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood (2007) 1.14
Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood (2005) 1.13
Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem (2004) 1.12
Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost (2006) 1.12
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood (2006) 1.11
Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke (2005) 1.11
Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier. Am J Respir Crit Care Med (2010) 1.10
uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res (2008) 1.09
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther (2009) 1.05
Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood (2010) 1.04
Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem (2003) 1.03
Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med (2009) 1.03
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab (2009) 1.02
Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem (2003) 1.02
Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem (2002) 1.02
tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. Neurol Res (2011) 1.01
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood (2002) 1.01
The kringle stabilizes urokinase binding to the urokinase receptor. Blood (2003) 1.00
Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program (2010) 1.00
The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition. J Pharmacol Exp Ther (2007) 1.00
Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders. J Neurochem (2010) 0.98
A stochastic algorithm for global optimization and for best populations: a test case of side chains in proteins. Proc Natl Acad Sci U S A (2002) 0.97
Interactions of platelet factor 4 with the vessel wall. Semin Thromb Hemost (2004) 0.94
Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo. J Pharmacol Exp Ther (2005) 0.94
Regulation of airway contractility by plasminogen activators through N-methyl-D-aspartate receptor-1. Am J Respir Cell Mol Biol (2010) 0.93
Induction of tissue factor by urokinase in lung epithelial cells and in the lungs. Am J Respir Crit Care Med (2010) 0.93
PF4/heparin complexes are T cell-dependent antigens. Blood (2005) 0.93
Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury. J Neurotrauma (2009) 0.93
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood (2013) 0.93
Pathogenesis of heparin-induced thrombocytopenia and thrombosis. Autoimmun Rev (2002) 0.93
Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci U S A (2013) 0.93
Advanced drug delivery systems for antithrombotic agents. Blood (2013) 0.92
Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury. J Immunol (2006) 0.92
Insulin and glucagon share the same mechanism of neuroprotection in diabetic rats: role of glutamate. Am J Physiol Regul Integr Comp Physiol (2011) 0.91
Urokinase induces activation of STAT3 in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol (2006) 0.91
Glucagon protects against impaired NMDA-mediated cerebrovasodilation and cerebral autoregulation during hypotension after brain injury by activating cAMP protein kinase A and inhibiting upregulation of tPA. J Neurotrauma (2011) 0.91
Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy. J Proteome Res (2007) 0.91
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol Biol Cell (2013) 0.90
Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor. J Biol Chem (2004) 0.90
Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model. Curr Cancer Drug Targets (2013) 0.90
Neuroprotection by glucagon: role of gluconeogenesis. J Neurosurg (2010) 0.90
Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model. Small (2013) 0.90
The role of surface PF4: glycosaminoglycan complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT). Pathophysiol Haemost Thromb (2006) 0.89
Novel diagnostic assays for heparin-induced thrombocytopenia. Blood (2013) 0.89
Urokinase-type plasminogen activator inhibits efferocytosis of neutrophils. Am J Respir Crit Care Med (2010) 0.88